Department of Emergency Medicine, Mount Sinai School of Medicine, New York, NY.
Ann Emerg Med. 2013 Oct;62(4):293-302.e10. doi: 10.1016/j.annemergmed.2013.02.004. Epub 2013 Apr 3.
We determine whether emergency provider attitudes and demographics are associated with adherence to national guidelines for the management of acute sickle cell disease pain.
We conducted a cross-sectional survey of emergency providers at the 2011 annual American College of Emergency Physicians Scientific Assembly, using a validated instrument to assess provider attitudes and self-reported analgesic practices toward patients with sickle cell disease. Multivariable, relative risk regressions were used to identify factors associated with adherence to guidelines.
There were 722 eligible participants, with a 93% complete response rate. Most providers self-reported adherence to the cornerstones of sickle cell disease pain management, including parenteral opioids (90%) and redosing opioids within 30 minutes if analgesia is inadequate (85%). Self-reported adherence was lower for other recommendations, including use of patient-controlled analgesia, acetaminophen, non-steroidal anti-inflammatory drugs and hypotonic fluids for euvolemic patients. Emergency providers in the highest quartile of negative attitudes were 20% less likely to redose opioids within 30 minutes for inadequate analgesia (risk ratio 0.8; 95% confidence interval [CI] 0.7 to 0.9). High-volume providers (those who treat more than 1 sickle cell disease patient per week), were less likely to redose opioids within 30 minutes for inadequate analgesia (risk ratio 0.9; 95% CI 0.8 to 0.9). Pediatric providers were 6.6 times more likely to use patient-controlled analgesia for analgesia (95% CI 2.6 to 16.6).
The majority of emergency providers report that they adhere to national guidelines about use of opioids for sickle cell disease-related acute pain episodes. Other recommendations have less penetration. Negative attitudes toward individuals with sickle cell disease are associated with lower adherence to guidelines.
我们确定急诊提供者的态度和人口统计学特征是否与遵守急性镰状细胞病疼痛管理的国家指南有关。
我们对 2011 年美国急诊医师学院科学大会的急诊提供者进行了横断面调查,使用经过验证的工具评估提供者对镰状细胞病患者的态度和自我报告的镇痛实践。使用多变量相对风险回归来确定与指南遵守相关的因素。
共有 722 名符合条件的参与者,完整回复率为 93%。大多数提供者自我报告遵守镰状细胞病疼痛管理的基石,包括静脉内阿片类药物(90%)和如果镇痛不足在 30 分钟内重新给予阿片类药物(85%)。自我报告的遵守率较低的其他建议包括使用患者自控镇痛、对乙酰氨基酚、非甾体抗炎药和低张液体用于血容量正常的患者。在态度最消极的四分位数中,提供者在镇痛不足的情况下在 30 分钟内重新给予阿片类药物的可能性降低 20%(风险比 0.8;95%置信区间 [CI] 0.7 至 0.9)。高容量提供者(每周治疗超过 1 例镰状细胞病患者的提供者)在镇痛不足的情况下在 30 分钟内重新给予阿片类药物的可能性降低 90%(风险比 0.9;95% CI 0.8 至 0.9)。儿科提供者使用患者自控镇痛进行镇痛的可能性高 6.6 倍(95% CI 2.6 至 16.6)。
大多数急诊提供者报告他们遵守了关于使用阿片类药物治疗镰状细胞病相关急性疼痛发作的国家指南。其他建议的普及率较低。对镰状细胞病患者的负面态度与较低的指南遵守率有关。